Skip to content

Optimal Concentration of Nalbuphine Combined with Ropivacaine in Epidural Labor Analgesia

Effect of Nalbuphine at Different Concentrations on Median Effective Concentration(EC50) of Ropivacaine in Labor Epidural Analgesia: A Safety and Effectiveness Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052044
Enrollment
Unknown
Registered
2021-10-15
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labor analgesia

Interventions

Group 1:Ropivacaine 0.1% and Nabuphine 0.3ug/ml
Group 2:Ropivacaine 0.1% and Nabuphine 0.4ug/ml
Group 3:Ropivacaine 0.1% and Nabuphine 0.5ug/ml
Group 4:Ropivacaine 0.1% and Nabuphine 0.6ug/ml
Control group:Ropivacaine 0.1%

Sponsors

Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Mature primiparity; 2. ASA I-II; 3. Single birth; 4. Spontaneous labor; 5. Aged 20-45 years; 6. Height 150-170 cm; 7. Body mass index (BMI) 24-30 kg/m^2; 8. Cervical dilation of 2-5 cm during the incubation period of labor; 9. Heart, liver, kidney, blood and other test indicators are all within the normal range.

Exclusion criteria

Exclusion criteria: 1. Important organs have primary diseases, such as nervous system diseases or neuropathy; 2. The parturient cannot cooperate with the spinal canal puncture, such as a history of mental illness; 3. There are contraindications to spinal block, such as coagulation dysfunction, infection or injury at the puncture site, uncorrected maternal hypovolemia or hypotension, increased intracranial pressure, severe spinal deformity, etc.; 4. Hypersensitivity to local anesthetics or opioids; 5. ontraindication of epidural anesthesis.

Design outcomes

Primary

MeasureTime frame
ED50 (median effective dose);Visual Analogu Scale;Modified Bromage Score;Sedation score;

Countries

China

Contacts

Public ContactLiu Xiaoling

Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine

mzlxl0620@zcmu.edu.cn+86 15968160316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026